NCT01669798View on ClinicalTrials.gov

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 10, 2017

Study Completion Date

February 28, 2018

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

BIBF 1120

PO 200mg BID

Trial Locations (3)

22908

University of Virginia, Charlottesville

23502

Virginia Oncology Associates, Norfolk

27710

Duke Cancer Institute, Durham

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

AA Secord

OTHER

NCT01669798 - BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter